Shares Plunge 28% After $4 Million Private Placement 

TLDR

• SILO shares plunged 28% to $5.57 following a $4 million financing deal.

• Silo Pharma will issue 619,965 shares alongside two separate warrant series.

• Both warrant series carry a $6.21 exercise price and become active immediately.

• Exercising all warrants could generate another $7.7 million for Silo Pharma.

• Silo Pharma will use net proceeds for working capital and general operations.

Silo Pharma shares plunged nearly 28% after the company announced a $4 million private placement. SILO fell to $5.57 during morning trading and later stabilized near $5.50. The financing includes common shares and warrants that could expand the company’s outstanding share count.

Silo Pharma, Inc., SILO

Silo Pharma Stock Falls After Private Placement

Silo Pharma agreed to issue 619,965 common shares or pre-funded warrants through the private placement. Each security package carries a purchase price of $6.452 under Nasdaq’s at-the-market pricing rules. The company also included two separate warrant series within the transaction.

Series A-3 warrants allow holders to purchase up to 619,965 additional common shares. Meanwhile, Series A-4 warrants cover the same number of shares but have a shorter duration. Both warrant series carry an exercise price of $6.21 per share.

The warrants become exercisable immediately after issuance, giving holders access to additional shares. Series A-3 warrants will expire five years after the resale registration statement becomes effective. However, Series A-4 warrants will expire 18 months after that effective date.

Offering Could Generate Additional Proceeds

Silo Pharma expects the private placement to generate approximately $4 million in gross proceeds. The total excludes placement agent fees and other expenses connected with the transaction. H.C. Wainwright serves as the exclusive placement agent for the offering.

The company could receive another $7.7 million if holders exercise every warrant using cash. Warrant exercises depend on market conditions and the decisions of individual holders. Therefore, the company may receive none of those potential additional proceeds.

Silo Pharma expects the transaction to close around July 10, subject to standard closing conditions. The company plans to direct the net proceeds toward working capital and general corporate purposes. Those funds could support operations while its drug programs remain in development.

Securities Require Resale Registration

Silo Pharma offered the securities through exemptions under Section 4(a)(2) and Regulation D. The company has not registered the shares or warrants under federal or applicable state securities laws. Consequently, buyers cannot freely resell them without registration or another available exemption.

The company entered a registration rights agreement covering the securities issued through the placement. Under that agreement, Silo Pharma must file registration statements with the Securities and Exchange Commission. Those filings will cover the resale of shares and stock underlying the warrants.

Private placements can pressure small biotechnology stocks because they increase the number of potential shares. Additional shares can reduce existing ownership percentages and weigh on per-share market value. SILO’s steep decline reflected the market’s response to that possible dilution.

Silo Pharma Develops CNS Treatments

Silo Pharma operates as a developmental-stage biopharmaceutical company focused on underserved medical conditions. Its research targets psychiatric disorders, chronic pain and diseases affecting the central nervous system. The company has not yet established a portfolio of approved commercial treatments.

Its leading programs include SPC-15, which targets post-traumatic stress disorder and related stress conditions. The portfolio also includes SP-26 for fibromyalgia and chronic pain management. Silo Pharma holds a preclinical asset focused on Alzheimer’s disease.

Drug development requires sustained funding because clinical studies and regulatory work often involve significant costs. Silo Pharma relies on financing transactions to support research and corporate operations. The latest placement provides fresh capital but introduces substantial potential dilution.